*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Ascletis Pharma Inc.**
**歌禮製藥有限公司**
*(incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 1672)**

# VOLUNTARY ANNOUNCEMENT

# ASCLETIS ANNOUNCES ORAL DISCUSSION OF ASC36_35 FDC PRECLINICAL DATA DEMONSTRATING SUPERIOR WEIGHT LOSS TO ELORALINTIDE/TIRZEPATIDE COMBINATION AT THE 62ND EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD) ANNUAL MEETING

– *Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model.*

This announcement is made by Ascletis Pharma Inc. (the "**Company**" or "**Ascletis**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces that preclinical data of ASC36_35 FDC, a once-monthly injection co-formulation of ASC36, a peptide amylin receptor agonist, and ASC35, a peptide GLP-1R/GIPR agonist, for the treatment of obesity, will be presented in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting being held in Milan, Italy. The data demonstrate superior weight loss to the eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model.

**Details of the Short Oral Discussion**

**Abstract Title:** Co-formulation of ASC36 and ASC35, once-monthly amylin receptor agonist and GLP-1R/GIPR agonist, demonstrated superior weight loss to eloralintide/tirzepatide combo in DIO rats

**Short Oral Discussion Event F**

**Short Oral Discussion Session:** SO 066 Emerging agents: amylin, oral molecules and beyond

Short Oral Discussion Station 11

**Presentation Time:** Thursday, October 1, 2026, 14:00 – 15:00 CEST

**Presentation Number:** 768

"We believe the co-formulation of ASC36 and ASC35 has the potential to lead to greater weight loss in people with obesity than eloralintide/tirzepatide combination can achieve, based on these preclinical data," said Jinzi Jason Wu, Ph.D., Founder, Chairman of the Board and chief executive officer of Ascletis, "The selection of these data for oral discussion at EASD 2026 reflects the importance of advancing new treatment options for patients with obesity."

**About ASC36_35 FDC**

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR. ASC36_35 FDC once-monthly co-formulation is Self-Assembling Lipid Depot (SALD) formulation, developed in-house utilizing Ascletis' Ultra-Long-Acting Platform (ULAP) technology.

**About the European Association for the Study of Diabetes (EASD)**

Founded in 1965 and based in Düsseldorf, Germany, the European Association for the Study of Diabetes (EASD) aims to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. The EASD Annual Meeting features groundbreaking basic research, cutting-edge clinical trial results and in-depth expert debates. The 62nd EASD Annual Meeting will be held in Milan, Italy, from September 28 to October 2, 2026.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC36_35 FDC, ASC35 and/or ASC36 successfully.

By order of the Board
**Ascletis Pharma Inc.**
**歌禮製藥有限公司**
**Jinzi Jason WU**
*Chairman*

Hong Kong
July 23, 2026

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*